0000315545-21-000001.txt : 20210830 0000315545-21-000001.hdr.sgml : 20210830 20210830160244 ACCESSION NUMBER: 0000315545-21-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210830 DATE AS OF CHANGE: 20210830 EFFECTIVENESS DATE: 20210830 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000315545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900031917 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-411710 FILM NUMBER: 211223544 BUSINESS ADDRESS: STREET 1: 10025 INVESTMENT DRIVE STREET 2: SUITE 250 CITY: KNOXVILLE STATE: TN ZIP: 37932 BUSINESS PHONE: 865-769-4011 MAIL ADDRESS: STREET 1: 10025 INVESTMENT DRIVE STREET 2: SUITE 250 CITY: KNOXVILLE STATE: TN ZIP: 37932 FORMER COMPANY: FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020417 FORMER COMPANY: FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC DATE OF NAME CHANGE: 20011126 FORMER COMPANY: FORMER CONFORMED NAME: SPM GROUP INC DATE OF NAME CHANGE: 19920703 D 1 primary_doc.xml X0708 D LIVE 0000315545 PROVECTUS BIOPHARMACEUTICALS, INC. 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN TENNESSEE 37932 866-594-5999 DELAWARE PROVECTUS PHARMACEUTICALS INC ZAMAGE DIGITAL IMAGING INC SPM GROUP INC Corporation true Webster Bailey 10025 Investment Drive Suite 250 Knoxville TN TENNESSEE 37932 Director Bruce Horowitz 10025 Investment Drive Suite 250 Knoxville TN TENNESSEE 37932 Executive Officer Director John Lacey, III 10025 Investment Drive Suite 250 Knoxville TN TENNESSEE 37932 Director Ed Pershing 10025 Investment Drive Suite 250 Knoxville TN TENNESSEE 37932 Director Dominic Rodrigues 10025 Investment Drive Suite 250 Knoxville TN TENNESSEE 37932 Director Heather Raines 10025 Investment Drive Suite 250 Knoxville TN TENNESSEE 37932 Executive Officer Eric Wachter 10025 Investment Drive Suite 250 Knoxville TN TENNESSEE 37932 Executive Officer Pharmaceuticals No Revenues 06b false 2021-08-16 false true true false 0 5000000 200000 4800000 false 1 0 0 0 Proceeds will be used to fund the Company's drug discovery and development program, as currently constituted and envisioned, and to fund the Company's general and administrative expenses. false PROVECTUS BIOPHARMACEUTICALS, INC. /s/ Heather Raines Heather Raines Chief Financial Officer 2021-08-30